News
Pfizer beats in Q2 earnings, reaffirms 2025 outlook
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 billion in revenues. The company reported revenues of $14.7 billion, compared to Wall Street expectations of $13.5 billion, and earnings per share of $0.78, versus estimates of $0.58 per share.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of ...
CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
Pfizer Inc. (NYSE:PFE) is one of the top cheap pharmaceutical stocks to buy now. On June 25, Pfizer Inc. (NYSE:PFE) announced ...
Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...
In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...
In terms of fundamentals, Pfizer currently boasts a market capitalization of $132 billion. Over the last twelve months, the company generated $62 billion in revenue and sustained operational ...
Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.
It's been a very nasty slump for shares of Pfizer (NYSE:PFE), which recently touched down with new 52-week lows of around $39 and change per share (now trading at $40.10).
Pfizer Inc. (NYSE:PFE) is one of the stocks in Jim Cramer’s game plan for this week. Cramer mentioned the company during the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback